MedCity News October 23, 2024
For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcare providers to offer education on herbal alternatives and consider these as part of the broader treatment conversation.
Terns Pharmaceuticals is making headlines with promising early results from its experimental GLP-1 obesity drug, which led to a 5.5% reduction in body weight in a small study. Positioned as a potential oral alternative to popular injectable weight loss medications like Ozempic, this new drug may soon offer another option for those seeking medical interventions for obesity. With larger trials on the horizon, the excitement around pharmaceutical treatments for weight loss continues to grow.
The economic...
Today's Sponsors
Today's Sponsor